ArticlePloS one2026
An interpretable machine learning framework for adverse drug reaction prediction from drug-target interactions.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-method statistical signal aggregation with machine learning for severity classification of neonatal adverse drug reactions.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Immune checkpoint inhibitor-related thyroid dysfunction during treatment of lung cancer: a disproportionality analysis based on the FDA adverse event reporting system.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdverse drug reactions (ADRs) present challenges to patient safety and healthcare systems. Current pharmacovigilance methods, such as the Yellow Card Scheme (YCS), provide valuable post-marketing data, but the mechanistic causes of these ADRs are not fully understood. Leveraging drug-target interaction data with interpretable machine learning offers a promising approach to anticipate ADRs and understand their underlying mechanisms.
objectiveThis study proposes an interpretable machine learning (ML) framework to predict significant ADRs using drug-target interaction data. The framework aims to identify key pharmacological relationships, helping to inform drug safety.
methodsDrug-target interaction data from STITCH was combined with ADR reports from the YCS. Disproportionality analysis identified significant ADR signals which were used to train Random Forest classifiers across System Organ Class (SOC) categories. Class imbalance was addressed with SMOTE and Tomek, and Bayesian optimisation refined hyperparameters. Feature importance scores provided interpretability, and the top features were validated using known target-disease associations from DisGeNET.
resultsPrediction performance varied across SOC categories, with ROC AUC scores up to 0.94. Feature importance analysis identified pharmacologically relevant targets, validated using DisGeNET and comparisons with SIDER highlighted the added value of real-world data.
conclusionsThe interpretable ML framework links drug-target interactions to ADRs, offering a promising approach for predictive pharmacovigilance (PPV) and supporting safer drug development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.